Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan
Copyright © 2020 Elsevier Ltd. All rights reserved..
Coronavirus disease 2019 (COVID-19) is a disease spreading rapidly in Sudan, the rest of the African continent and the world with no known definitive treatment or vaccines. However, among many treatment interventions being tested globally, beneficial effects and clinical improvements have been reported when convalescent plasma is used for treating COVID-19 patients. We prepared a guiding protocol for treating early to moderate COVID-19 patients with plasma transfusion from convalescent COVID-19 patients. This protocol was deduced based on previously published reports and studies that evaluated and tested convalescent plasma as a prospective therapy for COVID-19 patients. The protocol covers instructions on patient and donor selection criteria, plasma harvesting, plasma product specifications, dosage and precautions for convalescent plasma collection and transfusion process. Altogether, we prepared a treatment protocol that is tailored to the context of Sudan to be adopted by Sudan's health authority. Moreover, it will also provide reference for researchers to design open label clinical trials for convalescent plasma transfusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:59 |
|---|---|
| Enthalten in: |
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis - 59(2020), 6 vom: 30. Dez., Seite 102918 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hassan, Mozan Osman [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 21.12.2020 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.transci.2020.102918 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31473242X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31473242X | ||
| 003 | DE-627 | ||
| 005 | 20231225153356.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.transci.2020.102918 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1049.xml |
| 035 | |a (DE-627)NLM31473242X | ||
| 035 | |a (NLM)32900597 | ||
| 035 | |a (PII)S1473-0502(20)30232-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hassan, Mozan Osman |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Convalescent plasma as a treatment modality for coronavirus disease 2019 in Sudan |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.12.2020 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) is a disease spreading rapidly in Sudan, the rest of the African continent and the world with no known definitive treatment or vaccines. However, among many treatment interventions being tested globally, beneficial effects and clinical improvements have been reported when convalescent plasma is used for treating COVID-19 patients. We prepared a guiding protocol for treating early to moderate COVID-19 patients with plasma transfusion from convalescent COVID-19 patients. This protocol was deduced based on previously published reports and studies that evaluated and tested convalescent plasma as a prospective therapy for COVID-19 patients. The protocol covers instructions on patient and donor selection criteria, plasma harvesting, plasma product specifications, dosage and precautions for convalescent plasma collection and transfusion process. Altogether, we prepared a treatment protocol that is tailored to the context of Sudan to be adopted by Sudan's health authority. Moreover, it will also provide reference for researchers to design open label clinical trials for convalescent plasma transfusion | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Convalescent plasma | |
| 650 | 4 | |a Protocol | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Treatment | |
| 700 | 1 | |a Osman, Asma Ahmed |e verfasserin |4 aut | |
| 700 | 1 | |a Elbasit, Hana Elsir Abd |e verfasserin |4 aut | |
| 700 | 1 | |a Hassan, Hanan Elsamani |e verfasserin |4 aut | |
| 700 | 1 | |a Rufai, Hala |e verfasserin |4 aut | |
| 700 | 1 | |a Satti, Maria M M |e verfasserin |4 aut | |
| 700 | 1 | |a Elnegoumi, Musab |e verfasserin |4 aut | |
| 700 | 1 | |a Idris, Roaa |e verfasserin |4 aut | |
| 700 | 1 | |a Musa, Ashraf |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Abdelhakam H |e verfasserin |4 aut | |
| 700 | 1 | |a Zroog, Susan Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Altayb, Abduelbagi D A |e verfasserin |4 aut | |
| 700 | 1 | |a Khairy, Amna |e verfasserin |4 aut | |
| 700 | 1 | |a Allam, Mushal |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelhalim, Asaad Tageldein Idris |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis |d 2001 |g 59(2020), 6 vom: 30. Dez., Seite 102918 |w (DE-627)NLM114008043 |x 1473-0502 |7 nnns |
| 773 | 1 | 8 | |g volume:59 |g year:2020 |g number:6 |g day:30 |g month:12 |g pages:102918 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.transci.2020.102918 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 59 |j 2020 |e 6 |b 30 |c 12 |h 102918 | ||